Ifosfamide in pediatric malignancies

Area of Science:

• Pediatric Oncology
• Medical Chemotherapy
• Pharmacology

Background:

• Alkylating agents are crucial in pediatric cancer chemotherapy, especially for sarcomas.
• High-dose ifosfamide, a cyclophosphamide analog, is now used with mesna uroprotection.
• This has led to its adoption over conventional-dose cyclophosphamide in certain regimens.

Purpose of the Study:

• To evaluate the efficacy of ifosfamide-containing chemotherapy regimens in pediatric malignancies.
• To assess if high-dose ifosfamide improves response rates and survival in specific pediatric cancers.
• To determine the role of ifosfamide as a salvage regimen in refractory germ cell tumors.

Main Methods:

• Analysis of clinical trial data involving ifosfamide-based combination chemotherapy.
• Comparison of outcomes between ifosfamide-containing regimens and conventional treatments.
• Evaluation of response rates, disease-free survival, and salvage therapy effectiveness.

Main Results:

• Ifosfamide-containing regimens increased response and disease-free survival by 15-20% in poor-prognosis pediatric sarcomas (Ewing's, soft tissue).
• Ifosfamide and etoposide combination is effective salvage therapy for resistant germ cell tumors.
• No significant improvement in prognosis was observed for stage IV disseminated neuroblastoma with ifosfamide regimens.

Conclusions:

• High-dose ifosfamide demonstrates significant benefit in specific pediatric sarcomas and as salvage for germ cell tumors.
• The role of ifosfamide in other pediatric cancers like osteosarcoma and lymphomas requires further investigation.
• Long-term risks of late sequelae from high-dose alkylating agents remain unknown.